Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab

References

• Jaffe E S, Harris N E, Stein H, et al. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon 2001
   Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Shipp M A, Ross K N, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, et al. Expression of PKC-β or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18: 1377–1384
   PubMed Web of Science ®Google Scholar
• Espinosa I, Briones J, Bordes R, et al. Membrane PKC-β 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. Ann Hematol 2006; 85: 597–603
   PubMed Web of Science ®Google Scholar
• Schaffel R, Morais J C, Biasoli I, et al. PKC-β II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Mod Pathol 2007; 20: 326–330
   PubMed Web of Science ®Google Scholar
• Saez A-I, Saez A-J, Artiga M-J, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004; 164: 613–622
   PubMed Web of Science ®Google Scholar
• Fridberg M, Servin A, Anagnostaki L, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma 2007; 48: 2221–2232
   PubMed Web of Science ®Google Scholar
• Clemens M J, Trayner I, Menaya J. The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation. J Cell Sci 1992; 103(Part 4)881–887
   PubMed Web of Science ®Google Scholar
• Martelli A M, Evangelisti C, Nyakern M, et al. Nuclear protein kinase C. Biochim Biophys Acta 2006; 1761: 542–551
   PubMed Web of Science ®Google Scholar
• Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cβ-deficient mice. Science 1996; 273: 788–791
   PubMed Web of Science ®Google Scholar
• Su T T, Guo B, Kawakami Y, et al. PKC-β controls I κ B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3: 780–786
   PubMed Web of Science ®Google Scholar
• Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C {β} controls nuclear factor {κ}B activation in B cells through selective regulation of the I{κ}B kinase {α}. J Exp Med 2002; 195: 1647–1652
   PubMed Web of Science ®Google Scholar
• Robertson M J, Kahl B S, Vose J M, et al. Phase II study of enzastaurin, a protein kinase C β inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741–1746
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Farinha P, Hsi E D, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008; 26: 447–454
   PubMed Web of Science ®Google Scholar
• Lossos I S, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995–1007
   PubMed Web of Science ®Google Scholar
• Sehn L H, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284
   PubMed Web of Science ®Google Scholar
• Nyman H, Adde M, Karjalainen-Lindsberg M L, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930–4935
   PubMed Web of Science ®Google Scholar
• Winter J N, Weller E A, Horning S J, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213
   PubMed Web of Science ®Google Scholar